Jan 19 (Reuters) - Genmab A/S:
* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA
* GENMAB - FDA HAS ASSIGNED PDUFA TARGET DATE OF MAY 21, 2018 TO TAKE A DECISION ON DARATUMUMAB IN THE INDICATION Source text for Eikon: Further company coverage:
 